|
See related Renvela information |
|
|
|
Manufacturer |
Genzyme |
|
Distributor |
Hong Kong: DKSH |
|
Contents |
Sevelamer carbonate |
|
Indications |
Control of hyperphosphataemia in patients on haemodialysis or peritoneal dialysis or w/ chronic kidney disease not on dialysis w/ serum P ≥1.78 mmol/L. |
|
Dosage |
Patients w/ serum P levels >2.42 mmol/L Total daily dose: 4.8 g, 1.78-2.42 mmol/L Total daily dose: 2.4 g. All doses to be given tds. |
|
Administration |
Should be taken with food (Tab: Swallow whole, do not chew/crush/divide. Powd: Disperse in 60 mL water, ingest w/in 30 min after prep.). |
|
Contraindications |
Hypophosphataemia. Bowel obstruction. |
|
Special Precautions |
Patients w/ chronic kidney disease not on dialysis w/ serum P level <1.78 mmol/L. Dysphagia; swallowing, severe GI motility disorders; active inflammatory bowel disease, major GIT surgery. Monitor levels of fat soluble vit, folic acid, serum Ca & bicarbonate, TSH. Patients on antiarrhythmics & anticonvulsants. Pregnancy & lactation. |
|
Adverse Drug Reactions |
Nausea, vomiting, upper abdominal pain, constipation.
View ADR Monitoring Form |
|
Drug Interactions |
Ciprofloxacin, ciclosporin, mycophenolate mofetil, tacrolimus.
View more drug interactions with Renvela |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
ATC Classification |
V03AE02 - sevelamer ; Belongs to the class of drugs used in the treatment of hyperkalemia and hyperphosphatemia. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Renvela tablet |
|
|
Renvela powder for oral suspension |
|
|
|
Manufacturer: |
Genzyme |
|
Distributor: |
Hong Kong: DKSH
|
|
|
|
